- Home
- SGHT vs ACCD Comparison
SGHT vs ACCD Comparison
Compare SGHT & ACCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- ACCD
- Stock Information
- Founded
- SGHT 2011
- ACCD 2007
- Country
- SGHT United States
- ACCD United States
- Employees
- SGHT N/A
- ACCD N/A
- Industry
- SGHT Medical Specialities
- ACCD Business Services
- Sector
- SGHT Health Care
- ACCD Consumer Discretionary
- Exchange
- SGHT Nasdaq
- ACCD Nasdaq
- Market Cap
- SGHT 304.4M
- ACCD 353.6M
- IPO Year
- SGHT 2021
- ACCD 2020
- Fundamental
- Price
- SGHT $5.62
- ACCD $3.36
- Analyst Decision
- SGHT Buy
- ACCD Buy
- Analyst Count
- SGHT 6
- ACCD 12
- Target Price
- SGHT $7.20
- ACCD $9.04
- AVG Volume (30 Days)
- SGHT 144.8K
- ACCD 1.6M
- Earning Date
- SGHT 11-07-2024
- ACCD 10-08-2024
- Dividend Yield
- SGHT N/A
- ACCD N/A
- EPS Growth
- SGHT N/A
- ACCD N/A
- EPS
- SGHT N/A
- ACCD N/A
- Revenue
- SGHT $79,395,000.00
- ACCD $441,028,000.00
- Revenue This Year
- SGHT $3.39
- ACCD $14.97
- Revenue Next Year
- SGHT $11.43
- ACCD $13.54
- P/E Ratio
- SGHT N/A
- ACCD N/A
- Revenue Growth
- SGHT N/A
- ACCD 16.04
- 52 Week Low
- SGHT $1.04
- ACCD $3.25
- 52 Week High
- SGHT $8.45
- ACCD $15.36
- Technical
- Relative Strength Index (RSI)
- SGHT 42.60
- ACCD 31.69
- Support Level
- SGHT $5.74
- ACCD $3.59
- Resistance Level
- SGHT $6.08
- ACCD $3.83
- Average True Range (ATR)
- SGHT 0.31
- ACCD 0.23
- MACD
- SGHT -0.00
- ACCD -0.04
- Stochastic Oscillator
- SGHT 32.58
- ACCD 8.46
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About ACCD Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.